AzTrials
AzTrials

Respiratory Distress Syndrome in Premature InfantNCT04359134

Combined Lung Ultrasounds and Transthoracic Electrical Bioimpedance in Preterm Infants With Respiratory Distress.

An observational study of Respiratory Distress Syndrome in Premature Infant and Patent Ductus Arteriosus After Premature Birth, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 2 sites in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Respiratory distress syndrome (RDS) is among the most common complications of preterm birth, and typically becomes manifested soon after birth. A failure of the rapid reuptake of fetal lung fluids after birth, with subsequent liquid retention in the alveolar space, together with the deficit of surfactant proteins… Read more about this study

Who is it for?
Ages 1 day to 7 days
How many people
60 participants
Where
2 sitesItaly
Study dates
10 Mar 2020to 5 Apr 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 day to 7 days
  • All sexes
  • Child

Study population: Preterm infants ≤34 weeks' gestation with respiratory dystress

Who may be able to join

  • 0-24 hours of life,
  • gestational age ≤34 weeks' gestation
  • diagnosis of respiratory distress
  • written informed consent obtained from parents/legal guardians of each infant.

Who cannot join

  • major congenital malformations, including congenital heart disease
  • meconium aspiration
  • pneumothorax
  • perinatal asphyxia/hypoxic-ischemic encephalopathy
  • concomitant use of experimental drugs

Trial locations and contacts

2 sites in 1 country.

Italy2 sites, 2 recruiting
  • S. Orsola-Malpighi University Hospital

    Bologna, Emilia-Romagna, 40138

    Silvia Martini, MD, 0039 051 2144774, silvia.martini9@unibo.it

    Silvia Galletti

    Recruiting
  • Niguarda Hospital

    Milan

    Italo Gatelli, 02/64442390, italofrancesco.gatelli@ospedaleniguarda.it

    Stefano Martinelli, 02/64442390, stefano.martinelli@ospedaleniguarda.it

    Recruiting

Other trials in Italy

About this study

Official title: Combined Evaluation of Pulmonary Fluids by Lung Ultrasounds and Transthoracic Electrical Bioimpedance in Preterm Infants With Respiratory Distress Syndrome

Respiratory distress syndrome (RDS) is among the most common complications of preterm birth, and typically becomes manifested soon after birth. A failure of the rapid reuptake of fetal lung fluids after birth, with subsequent liquid retention in the alveolar space, together with the deficit of surfactant proteins ensuing from lung immaturity represent the leading mechanisms for the development of RDS, which may require different levels of respiratory support.

An increasingly used method for the evaluation of the neonatal lung is pulmonary ultrasound, which allows assessing alveolar fluids and other pathological conditions in a non-invasive manner, and has been shown to predict the need for respiratory support and for surfactant administration in preterm infants with RDS. However, this method requires specific training, is operator-dependent and does not provide a trend able assessment over time.

Read more

Transthoracic electrical bioimpedance (TEB) allows continuous and non-invasive monitoring of static and dynamic thoracic fluids. It has been recently introduced in neonatal clinical practice to assess such hemodynamic parameters as cardiac output and also quantifies static thoracic fluids contents (TFC). This method provides continuous and non-operator dependent data on the pulmonary fluid status over time and does not require specific training.

The combination of lung ultrasound with TEB could open to new diagnostic and prognostic perspectives in preterm infants with RDS.

Read the detailed description

Introduction Respiratory distress syndrome (RDS) is among the most common complications of preterm birth, and typically becomes manifested soon after birth. The rapid reuptake of fetal lung fluids plays an important role in transitional events at birth. Most of this fluid is reabsorbed through epithelial alveolar cells by an active sodium transporter. Mechanical events play a role in this exchange too. A failure of the rapid reuptake of fetal lung fluids after birth, with subsequent liquid retention in the alveolar space, together with the deficit of surfactant proteins ensuing from lung immaturity represent the leading mechanisms for the development of RDS, which may require different levels of respiratory support, ranging from mechanical ventilation to less invasive modalities (nasal cannulas or continuous positive airway pressure (CPAP)).

An increasingly used method for lung evaluation in the newborn is lung ultrasound, which allows to evaluate the alveolar fluid and to differentiate among several pathological conditions (transient tachypnea of the newborn, meconium aspiration, respiratory distress syndrome, pneumothorax, and pleural effusion) and, in the preterm population, has also been proved to predict of the need for respiratory support and for surfactant administration. Compared to traditional radiological assessments, this non-invasive technique does not imply the use of X-ray; however, it requires specific training, it is operator-dependent and does not allow a continuous and trend able evaluation over time, but only serial assessments.

Transthoracic electrical bioimpedance (TEB) allows continuous, non-invasive and real-time monitoring of static and dynamic thoracic fluids. It has been recently introduced in neonatal clinical practice to monitor such hemodynamic parameters as cardiac output, providing useful clinical information in hospitalized preterm infants, or neonates undergoing hemodynamic procedures. This technique allows quantifying static thoracic fluid contents (TFC) in a non-invasive and continuous manner. Compared to ultrasound, this method provides continuous and non-operator dependent data on the lung fluid status over time and does not require specific training for its use and interpretation.

Current literature reported a significant correlation between TFC values and respiratory distress, but, to date, it has not been investigated whether this parameter may predict RDS evolution, or if it is influenced by specific neonatal characteristics associated with pulmonary overflow, such as the presence of a patent ductus arteriosus (PDA), which is a common finding over the transitional period, defined as the first 72 hours of life.

Combining lung ultrasound to transthoracic electrical bioimpedance could open to new diagnostic and prognostic perspectives in preterm infants with RDS during the first days of life.

Objectives:

  1. To evaluate the correlation between TFC, measured by transthoracic electrical bioimpedance (TEB), and a pulmonary ultrasound score, used for the evaluation of lung fluids in preterm infants with RDS in the Neonatal Intensive Care Unit.
  2. To assess whether the combination of TFC with a pulmonary ultrasound score can be predictive of RDS evolution over the next 24 hours (need for surfactant, need for mechanical ventilation vs. suspension of ventilatory support).
  3. Evaluation of pulmonary ultrasound score, TFC levels and left cardiac output in relation to the status of the ductus arteriosus (hemodynamically significant, restrictive or closed).

Methods:

Infants born at S. Orsola-Malpighi Hospital and Niguarda Hospital and admitted to the local Neonatal Intensive Care Units are consecutively enrolled in this observational prospective study if fulfilling the following eligibility criteria: gestational age ≤34 weeks' gestation, diagnosis of respiratory distress (defined by the need for respiratory support with nasal cannulas, nasal CPAP or mechanical ventilation), 0-24 hours of life, written informed consent obtained from parents/legal guardians of each infant.

The following conditions are considered as exclusion criteria: main congenital malformation, including congenital heart disease, meconium aspiration, pneumothorax, perinatal asphyxia/hypoxic-ischemic encephalopathy, concomitant use of experimental dugs.

Enrolled infants undergo serial lung and cardiac ultrasound evaluations at 0-24 (V1), at 24-48 (V2) and at 48-72 (V3)hours of life. A simultaneous evaluation of hemodynamic parameters and TFC by means of TEB is also performed.

Lung ultrasound findings are classified according to a validated pulmonary ultrasound score that takes into account six pulmonary fields (right upper anterior, right lower anterior, right lateral, left upper anterior, left lower anterior, left lateral). For each field a number is assigned:

  • 0: only A lines or <3 B lines
  • 1: ≥3 B lines
  • 2: crowded and confluent B lines with or without consolidations
  • 3: important consolidation If at 72 hours of life a hemodynamically relevant patent ductus arteriosus is still evident at cardiac ultrasound, the ultrasound and TEB monitoring are carried on until PDA closure.

Outcome: need for surfactant administration (and number of surfactant administrations), inhaled oxygen fraction, need for diuretic therapy, duration of ventilatory support with nasal canula/nasal CPAP/mechanical ventilation, duration of oxygen therapy, bronchopulmonary dysplasia at 36 weeks, duration of hospitalization and time for reach total enteral nutrition.

Statistic analysis: SPSS will be used for the statistical analysis. The diagnostic accuracy of TFC and of the ultrasound score for predicting the need for ventilatory support and for surfactant administration will be evaluated by area under ROC curve in order to find the optimal cut off value. The cardiac output values will be analyzed in relation to the state of the ductus arteriosus with Kruskal-Wallis test and included in a multivariate model in order to rule out the influence of confounding factors (for example the modality of ventilatory support). Significance level is set at p<0,05.

Keywords
respiratory distress, patent ductus arteriosus, preterm infants, transthoracic electrical bioimpedance, lung ultrasounds
Medical subject headings
Dyspnea, Ductus Arteriosus, Patent

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Correlation between lung ultrasound score and RDS evolution

    Pearson correlation analysis between the score of lung ultrasound and RDS evolution over the next 24 hours (defined by the need for surfactant or a step-up in the type of respiratory support).

    Measured: 0-24 hours of life

  2. Correlation between lung ultrasound score and RDS evolution

    Pearson correlation analysis between the score of lung ultrasound and RDS evolution over the next 24 hours (defined by the need for surfactant or a step-up in the type of respiratory support).

    Measured: 24-48 hours of life

  3. Correlation between lung ultrasound score and RDS evolution

    Pearson correlation analysis between the score of lung ultrasound and RDS evolution over the next 24 hours (defined by the need for surfactant or a step-up in the type of respiratory support).

    Measured: 48-72 hours of life

  4. Correlation between TFC and RDS evolution

    Pearson correlation analysis between TFC values and RDS evolution over the next 24 hours (defined by the need for surfactant or a step-up in the type of respiratory support).

    Measured: 0-24 hours of life

  5. Correlation between TFC and RDS evolution

    Pearson correlation analysis between TFC values and RDS evolution over the next 24 hours (defined by the need for surfactant or a step-up in the type of respiratory support).

    Measured: 24-48 hours of life

  6. Correlation between TFC and RDS evolution

    Pearson correlation analysis between TFC values and RDS evolution over the next 24 hours (defined by the need for surfactant or a step-up in the type of respiratory support).

    Measured: 48-72 hours of life

  7. Correlation between TFC and lung ultrasound score

    Pearson correlation analysis between TFC values and lung ultrasound score

    Measured: 0-24 hours of life

  8. Correlation between TFC and lung ultrasound score

    Pearson correlation analysis between TFC values and lung ultrasound score

    Measured: 24-48 hours of life

  9. Correlation between TFC and lung ultrasound score

    Pearson correlation analysis between TFC values and lung ultrasound score

    Measured: 48-72 hours of life

Secondary outcomes (1)
  1. Changes in TFC values and lung ultrasound score between time periods with patent and closed ductus arteriosus

    Changes in TFC and lung ultrasound scores between time periods with patent and closed ductus arteriosus

    Measured: 0-72 hours of life

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Apr 2020
  2. Study start10 Mar 2020
  3. Primary completion31 Mar 2022 (estimated)
  4. Study completion5 Apr 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04359134
Sponsor's protocol ID
Neo-POLM
Status last verified
Jul 2021
First submitted
17 Apr 2020
Last updated
28 Jul 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Respiratory Distress Syndrome in Premature Infant and Patent Ductus Arteriosus After Premature Birth, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 2 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 28 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Silvia Galletti (0039 051 2144774, silvia.galletti4@unibo.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Correlation between lung ultrasound score and RDS evolution (time frame: 0-24 hours of life). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in